How to master the correct usage and dosage of ibrutinib/Eco
Ibrutinib/Ibrutinib (Ibrutinib) is a BTK inhibitor. Correct usage and dosage are crucial to ensure efficacy and reduce adverse reactions. This drug is taken in oral form and patients must strictly follow the doctor's prescription.
In the treatment of mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), the recommended dose is 560 mg daily, i.e., four 140 mg capsules taken orally once daily until disease progression or intolerable toxicity occurs. In the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as Waldenstrom's macroglobulinemia (WM), the dose is 420 mg daily, equivalent to three 140 mg capsules. Patients usually take the medication at a fixed time, with or without food.

Dose design varies in the treatment of graft-versus-host disease (cGVHD). For patients 12 years old and above, the recommended dose is 420 mg daily; for pediatric patients 1 to 12 years old, the dose needs to be adjusted based on body surface area (BSA). The recommended dose is 240 mg/m², once daily, but the maximum dose does not exceed 420 mg. This dose adjustment method ensures that the drug can be effective in patients of different ages while minimizing adverse reactions.
During medication management, patients need to swallow the capsules whole and avoid breaking or chewing them to ensure stable release of the medication in the body. If the patient misses a dose, he or she should take it as soon as possible, but if it is close to the next dose time, no additional supplement is required.
In addition, doctors usually assess the patient's heart function, bleeding risk, and infection before using medication to ensure the safety of the medication. During the treatment process, if adverse reactions occur, the dose may need to be adjusted or the medication may be temporarily discontinued. In severe cases, permanent discontinuation may be considered. Therefore, patients must use it under the guidance of a doctor and avoid changing the dosage or medication method at will.
Reference materials:https://www.imbruvica.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)